How many steps a day lower the risk of early death?
Short answer
About 6,000 to 10,000 steps; fewer if older.
Pooled population studies link more steps to lower death risk, flattening near 6000-8000 steps at 60 and older and 8000-10 000 under 60. Some reviews saw no ceiling. These are links, not proof.
This page says what the research shows. It does not say whether you should walk a set number of steps.
Where the evidence stands
Each dot is one on-topic paper. Steps near the top answer the question more directly. Select a dot to see the study.
↑ Stronger evidence
-
Trials in people: death from any cause
Trials that measured death from any cause directly.
0Not done yet. This is the step that would answer the question.
-
Trials in people: other measures
Trials that measured other health or performance measures.
0None among the papers we read.
-
Trials in people: lab tests or safety
Trials that measured lab tests, side effects or safety.
0None among the papers we read.
-
Population studies
Studies that followed or surveyed groups of people. They show links, not causes.
10 -
Blood levels and genes
Studies that link blood levels or genes to health.
0None among the papers we read.
↓ Weaker evidence
- Points to benefit
- Mixed
- No difference
- No direction
- Points to harm
Not on the ladder: 7 reviews of many studies (shown below). Counts are papers, not people. Some studies appear in more than one paper.
See every studyWhat we found
- Among adults 60 and older, death risk kept falling until 6000-8000 steps a day; among younger adults, until 8000-10 000 steps, in 15 pooled cohorts. Paluch 2022
- Compared with 2000 steps a day, 7000 steps a day was linked to a 47% lower risk of death from any cause; gains slowed after around 5000-7000 steps. Ding 2025
- Versus 2,000 steps a day, death risk was lower from 2,517 steps and lowest at 8,763 steps, where the hazard ratio was 0.40 (less than half). Stens 2023
- Not every review found a ceiling: one saw risk fall in a straight line from 2700 to 17,000 steps; another found the lowest risk above 12,500 steps. Jayedi 2022, Rodríguez-Gutiérrez 2024
What the research says
More steps went with fewer deaths
Every pooled analysis found that people who took more steps a day were less likely to die during follow-up. In 15 cohorts, hazard ratios fell from 0·60 to 0·47 across higher step groups. In seventeen cohorts, each 1000 more steps went with a 15% lower risk.
A hazard ratio of 0·47 means roughly half the risk of the lowest group. In UK Biobank's 78 500 adults, lower risk held for up to about 10 000 steps a day. These are links from population studies, not proof that steps cause longer life.
Studies: Paluch 2022, Banach 2023, Del Pozo Cruz 2022, Rahmati 2025, Rodríguez-Gutiérrez 2024
Where the drop in risk levels off
Three pooled analyses saw the drop flatten somewhere between about 5000 and 10 000 steps. One review of 31 studies placed the bend at around 5000-7000 steps. Another put the optimal dose at 8,763 steps.
A US cohort found similar risk at 8000-11999 steps (hazard ratio 0.41) and 12000 or more (0.44). In another, the benefit of reaching 8000 steps plateaued at 3 days a week.
Studies: Paluch 2022, Ding 2025, Stens 2023, Wang 2026, Inoue 2023
Benefit may differ by age and income
One pooled analysis of 15 cohorts found risk kept falling until 6000-8000 steps a day at 60 and older, but until 8000-10 000 steps under 60. Another said the best dose differed by age and sex.
In 7032 US adults, more steps went with lower death risk in every income group, but lower-income adults needed 1.2-2.3 times more steps for the same drop. The newest large review lacked age-specific analysis.
Studies: Paluch 2022, Rodríguez-Gutiérrez 2024, Del Pozo Cruz 2025, Ding 2025
Some reviews found no clear ceiling
Not all reviews agree on a plateau. One pooled 7 cohorts and found risk fell in a straight line from 2700 to 17,000 steps; 10,000 steps had a hazard ratio of 0.44. Another found the lowest risk above 12,500 steps (0.35).
A third, of seventeen cohorts, found risk kept dropping with more steps above 3867 a day. An umbrella review rated the steps evidence as suggestive, not convincing.
Studies: Jayedi 2022, Rodríguez-Gutiérrez 2024, Banach 2023, Rahmati 2025
Illness lowers steps, which clouds the link
In 57 people with advanced cancer, daily steps fell 16% in the week before a hospital stay or death, so illness itself can lower steps. One cohort lists this reverse causation and leftover confounding as limits.
In 46 people with lung scarring, more steps went with a more than halved risk of death. In COPD, each 1,000 more steps went with HR 0.80 for death or hospital stay. In Hispanic adults, under 7000 steps had no clear link to heart disease or death (HR 1.58, 0.85-2.93).
Studies: Manz 2024, Del Pozo Cruz 2025, Bahmer 2017, Durheim 2015, Alver 2024
What reviews of many studies found
Reviews pool or sum up earlier studies. They are not on the ladder, because they repeat studies already counted there.
Pooled review (meta-analysis) · Ding 2025
Reviewed 57 studies and pooled 31 from 24 cohorts. Compared with 2000 steps a day, 7000 steps went with 47% lower risk of death (14 studies). Risk flattened around 5000-7000 steps. Certainty rated moderate.
Pooled review (meta-analysis) · Banach 2023
Pooled seventeen cohorts with 226 889 people followed a median 7.1 years. Each 1000 more steps a day went with 15% lower risk of death (HR 0.85). Risk kept falling with more steps above 3867 a day.
Pooled review (meta-analysis) · Paluch 2022
Pooled participant-level data from 15 cohorts: 47 471 adults, 3013 deaths. The top step group had a hazard ratio of 0·47 versus the lowest. Risk flattened at 6000-8000 steps for ages 60 and older, 8000-10 000 for younger adults.
Systematic review · Rahmati 2025
Umbrella review of earlier meta-analyses on activity, sitting and death. Device-measured daily steps went with lower death from any cause (eHR = 0.44, range 0.35-0.56). It rated this evidence suggestive; none reached convincing.
How the research grew
The papers we read span 2015 to 2026. 9 of the 17 on-topic papers came out in 2024 to 2026.
- 2015
- 2017
- 2022
- 2023
- 2024
- 2025
- 2026
Each dot is one on-topic paper, colored by what it found. Rings mark key papers:
- 2015. Earliest here: steps linked to COPD death, hospital stays. Durheim 2015
- 2022. Dose-response review: risk fell steadily to 17,000 steps. Jayedi 2022
- 2022. 15-cohort pooled data: plateau differs by age. Paluch 2022
- 2023. Largest pooled sample: 226 889 people, seventeen cohorts. Banach 2023
- 2025. Newest big review: 7000 vs 2000 steps, 47% lower. Ding 2025
Who was studied
Who took part, and how many. There are no trials in people here. The largest population study had 78,500 people.
- Population, blood and gene studies
- 33,560 people · Del Pozo Cruz 2025
UK adults, average age 62, taking 8000 or fewer steps a day, with no heart disease or cancer - 14,399 people · Hamaya 2024
Women aged 62 and older without heart disease or cancer (average age 71.8) - 7,032 people · Del Pozo Cruz 2025
US adults aged 18-80 in a national health survey, grouped by family income - People in the study, log scale1101001,00010,000100,000
- Points to benefit
- Mixed
- No difference
- No direction
- Points to harm
Bars use a log scale: each step is ten times more people. Reviews, animal studies and papers with no count in the abstract are not shown.
Who funds this research
No relevant paper is a trial that assigned steps. Four of 17 list company ties: one review author had support from Apple, Google and iHealth, which sell step counters; others name drug or health firms. Ties did not change confidence.
- Company stake 4
- No disclosure in PubMed 4
- No stake declared 9
- Banach 2023Company stake
- Hamaya 2024Company stake
- Manz 2024Company stake
- Alver 2024Company stake
- Jayedi 2022No disclosure in PubMed
- Durheim 2015No disclosure in PubMed
- Del Pozo Cruz 2025No disclosure in PubMed
- Wang 2026No disclosure in PubMed
- Paluch 2022No stake declared
- Ding 2025No stake declared
- Stens 2023No stake declared
- Rahmati 2025No stake declared
- Rodríguez-Gutiérrez 2024No stake declared
- Del Pozo Cruz 2025No stake declared
- Del Pozo Cruz 2022No stake declared
- Inoue 2023No stake declared
- Bahmer 2017No stake declared
Funding rule. A stake is always shown. Confidence is lowered only when every supporting study comes from a party with a stake. "No disclosure in PubMed" means the PubMed record has no conflict-of-interest statement. It does not mean there is no conflict.
All 17 on-topic papers
Each paper shows what it tested, what it found, and who has a stake. Every paper also has its own page that explains how much it counts and how it fits. See every study as a list.
-
Steps to longevity: Association of daily total steps and bouted steps with all-cause mortality.
2,764 people · US adults, average age 49.4, in a national health survey
TestedCompared total daily steps (under 4000 to 12000+) and steps in 10-minute walks, followed 13 years for deaths
Versus under 4000 steps, HRs were 0.52 for 4000-7999, 0.41 for 8000-11999 and 0.44 for 12000 or more steps a day.
Points to benefitNo disclosure in PubMedAbstract onlyNo disclosure in PubMed.
-
Step Accumulation Patterns and Risk for Cardiovascular Events and Mortality Among Suboptimally Active Adults.
33,560 people · UK adults, average age 62, taking 8000 or fewer steps a day, with no heart disease or cancer
TestedCompared people by whether most steps came in short (under 5 min) or longer (15 min or more) walks, then followed for deaths
At 9.5 years, death rate fell with longer walks: 4.36% for bouts under 5 minutes, 1.83% for 5 to under 10, 0.84% for 10 to under 15, and 0.80% for 15 or more.
Points to benefitNo disclosure in PubMedAbstract onlyDisclosure forms are online, not in PubMed.
-
Unequal strides to longevity. The extra mile to health equity.
7,032 people · US adults aged 18-80 in a national health survey, grouped by family income
TestedMeasured daily steps with a movement sensor, compared death risk across income groups, median 5.9 years of follow-up
More steps went with lower death risk in all income groups. Low-income people needed 1.2-2.3 times more steps to get the same benefit as high-income people.
Points to benefitNo stake declaredAbstract onlyNo competing financial interests declared.
-
Time- vs Step-Based Physical Activity Metrics for Health.
14,399 people · Women aged 62 and older without heart disease or cancer (average age 71.8)
TestedWore a movement sensor for 7 days, then followed for deaths; compared step counts and minutes of hard activity
Each extra standard deviation of steps went with HR 0.74 for death from any cause. The top 3 step groups lived 2.36 months longer free of death at 9 years than the bottom group.
Points to benefitCompany stakeAbstract onlyOne author got consulting fees from DeSC Healthcare, Inc; other funding is from NIH.
-
Association of Remote Patient-Reported Outcomes and Step Counts With Hospitalization or Death Among Patients With Advanced Cancer Undergoing Chemotherapy: Secondary Analysis of the PROStep Randomized Trial.
57 people · Adults with advanced stomach, bowel or lung cancer on chemotherapy
TestedTracked symptoms and Fitbit steps and linked them to hospital stays or death
Each 1000 fewer steps went with 16% greater odds of hospital stay or death (aOR 1.2). Steps fell 16% in the week before.
Points to benefitCompany stakeAbstract onlyAuthors report ties to Genentech, GNS Healthcare, Onc.AI, Humana and others; not step-device makers.
-
Physical Activity, Cardiovascular Status, Mortality, and Prediabetes in Hispanic and Non-Hispanic Adults.
13,223 people · Hispanic and non-Hispanic adults with or without prediabetes
TestedLinked activity levels (including steps) to heart disease or death, whichever came first
Steps under 7000 vs 7000 or more had HR 1.58 for normal blood sugar and 1.08 for prediabetes, neither clear. Main result was about hard activity time.
No differenceCompany stakeAbstract onlyAuthors report fees from Fukuda Denshi, Kowa and RhythmX AI, and a Novo Nordisk grant.
-
Association of Daily Step Patterns With Mortality in US Adults.
3,101 people · US adults aged 20 and older in a national health survey
TestedCounted days per week with 8000 steps or more (0, 1-2, or 3-7 days) and followed for deaths for 10 years
Death risk was lower for 1-2 days (aRD -14.9%) and 3-7 days (aRD -16.5%) a week at 8000 steps than for 0 days. The benefit plateaued at 3 days a week.
Points to benefitNo stake declaredAbstract onlyAuthors report public grants only; no company ties.
-
Prospective Associations of Daily Step Counts and Intensity With Cancer and Cardiovascular Disease Incidence and Mortality and All-Cause Mortality.
78,500 people · UK adults aged 40 to 79 in a large health study
TestedWore a wrist movement sensor, then followed for about 7 years for deaths, cancer and heart disease
More daily steps went with lower risk of death from any cause, heart disease and cancer (all cause MRC -0.08) for up to about 10 000 steps. There were 2179 deaths.
Points to benefitNo stake declaredAbstract onlyConflict of interest: none reported.
-
Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis.
46 people · Adults with lung scarring disease (IPF), average age 67
TestedCounted steps a day with a sensor, then tracked survival for 3 years
20 of 46 died. Each standard deviation more steps a day went with a more than halved risk of death (HR < 0.50). Steps fell by 973 a day each year in survivors.
Points to benefitNo stake declaredAbstract onlyNo competing interests declared.
-
Population study: followed a groupDurheim et al., 2015Annals of the American Thoracic Society · PubMed
Six-minute-walk distance and accelerometry predict outcomes in chronic obstructive pulmonary disease independent of Global Initiative for Chronic Obstructive Lung Disease 2011 Group.
326 people · People with moderate to severe COPD
TestedLinked starting steps and walk distance to later hospital stays or death
Each 1,000 more steps was linked to HR 0.80 for COPD hospital stay or death from any cause.
Points to benefitNo disclosure in PubMedAbstract onlyNo disclosure in PubMed.
-
Daily steps and health outcomes in adults: a systematic review and dose-response meta-analysis.
31 studies · Adults in 24 groups of studies that tracked steps with a device
TestedCompared daily step counts (7000 steps vs 2000 steps) and later health outcomes including death
Death risk fell more slowly after about 5000-7000 steps a day. Compared with 2000 steps, 7000 steps a day went with 47% lower risk of death from any cause (HR 0·53).
Points to benefitNo stake declaredAbstract onlyNo competing interests declared; funded by Australian health research bodies.
-
Associations Between Exercise Training, Physical Activity, Sedentary Behaviour and Mortality: An Umbrella Review of Meta-Analyses.
48 studies · Adults in 48 earlier meta-analyses on exercise, activity and sitting
TestedReviewed earlier meta-analyses linking exercise, activity, sitting and death; steps were one measure
Device-measured daily steps went with lower death from any cause (eHR = 0.44). The review rated this evidence as suggestive, not convincing.
Points to benefitNo stake declaredAbstract onlyThe authors declare no conflicts of interest.
-
Daily steps and all-cause mortality: An umbrella review and meta-analysis.
14 studies · Adults in 14 cohort studies, plus 11 earlier reviews
TestedPooled studies of daily steps and death from any cause, per 1000 more steps
Risk of death was lower from 3143 steps a day, with HR 0.91 per 1000 more steps. The most active group (over 12,500 steps) had HR 0.35.
Points to benefitNo stake declaredAbstract onlyNo relevant financial or non-financial interests to disclose.
-
Pooled review (meta-analysis)Stens et al., 2023Journal of the American College of Cardiology · PubMed
Relationship of Daily Step Counts to All-Cause Mortality and Cardiovascular Events.
12 studies, 111,309 people · Adults in the general population from 12 studies
TestedCompared daily step counts with 2,000 steps a day as the reference, then looked at deaths and heart disease
Death risk was lower at 2,517 steps a day (aHR 0.92) and kept falling to about 8,763 steps a day (aHR 0.40) compared with 2,000 steps.
Points to benefitNo stake declaredAbstract onlyNo relevant relationships declared; funded by public grants.
-
The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis.
17 studies, 226,889 people · Generally healthy adults or adults at heart risk, from 17 studies
TestedCompared daily step counts and later death from any cause and from heart disease
Each 1000 more steps a day went with 15% lower risk of death (HR 0.85). Higher step groups had 48, 55 and 67% lower risk than the lowest group.
Points to benefitCompany stakeAbstract onlyOne author received research support from Apple, Google and iHealth, which sell step-counting devices; others list drug company ties.
-
Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts.
15 studies, 47,471 people · Adults aged 18 and older from 15 studies in several countries
TestedCompared people by how many steps they took a day (four groups, lowest group as the reference), then followed them for deaths
Compared with the lowest step group, the hazard ratio for death was 0·60 for group 2, 0·55 for group 3 and 0·47 for group 4. Risk kept falling until 6000-8000 steps a day in people 60 and older, and 8000-10 000 in younger adults.
Points to benefitNo stake declaredAbstract onlyNo competing interests relevant to steps; funded by US CDC and NIH grants.
-
Daily Step Count and All-Cause Mortality: A Dose-Response Meta-analysis of Prospective Cohort Studies.
7 studies · General population adults from 7 long-term studies
TestedPooled studies of daily steps and death from any cause
Each 1000 steps a day had HR 0.88 for death. Risk fell in a straight line from 2700 to 17,000 steps a day; HR for 10,000 steps was 0.44.
Points to benefitNo disclosure in PubMedAbstract onlyNo disclosure in PubMed.
37 papers we read and set aside as off topic
- Bizzozero-Peroni et al., 2024. Daily Step Count and Depression in Adults: A Systematic Review and Meta-Analysis. (pooled review (meta-analysis))
- Paluch et al., 2023. Prospective Association of Daily Steps With Cardiovascular Disease: A Harmonized Meta-Analysis. (pooled review (meta-analysis))
- Rouyard et al., 2025. Effects of workplace interventions on sedentary behaviour and physical activity: an umbrella review with meta-analyses and narrative synthesis. (pooled review (meta-analysis))
- Thompson et al., 2024. Increasing Activity After Stroke: A Randomized Controlled Trial of High-Intensity Walking and Step Activity Intervention. (randomized trial)
- Breuls et al., 2025. 1-year physical activity coaching programme in lung transplant recipients: an RCT. (randomized trial)
- Golbus et al., 2022. Understanding Baseline Physical Activity in Cardiac Rehabilitation Enrollees Using Mobile Health Technologies. (population study: one-time survey)
- Fanaroff et al., 2024. Effect of Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients at High Risk of Cardiovascular Events: The BE ACTIVE Randomized Controlled Trial. (randomized trial)
- Aldabayan et al., 2019. Pulmonary rehabilitation, physical activity and aortic stiffness in COPD. (trial, not randomized)
- Hamada et al., 2016. The effectiveness and safety of modest exercise in Japanese patients with chronic kidney disease: a single-armed interventional study. (trial, not randomized)
- Astley et al., 2021. Home-Based Exercise Training in Childhood-Onset Takayasu Arteritis: A Multicenter, Randomized, Controlled Trial. (randomized trial)
- Gremaud et al., 2018. Gamifying Accelerometer Use Increases Physical Activity Levels of Sedentary Office Workers. (randomized trial)
- Hartman et al., 2016. Improvement of physical activity after endobronchial valve treatment in emphysema patients. (randomized trial)
- Coelho-Júnior et al., 2026. Muscle failure and risk of adverse outcomes in older adults: a derivation and multicohort validation study. (population study: followed a group)
- Andrade et al., 2014. Maintaining high activity levels in sedentary adults with a reinforcement-thinning schedule. (randomized trial)
- Stevens-Lapsley et al., 2023. High-intensity home health physical therapy among older adult Veterans: A randomized controlled trial. (randomized trial)
- Rahimy et al., 2021. Phase II trial evaluating efficacy of a Fitbit program for improving the health of endometrial cancer survivors. (randomized trial)
- Kuhn et al., 2022. Increasing Daily Physical Activity and Its Effects on QTc Time in Severe to Very Severe COPD: A Secondary Analysis of a Randomised Controlled Trial. (randomized trial)
- Tiessen et al., 2013. Cost-effectiveness of cardiovascular risk management by practice nurses in primary care. (randomized trial)
- Sylvia et al., 2023. Healthy hearts healthy minds: A randomized trial of online interventions to improve physical activity. (randomized trial)
- O'Neill et al., 2018. Clinician-Facilitated Physical Activity Intervention Versus Pulmonary Rehabilitation for Improving Physical Activity in COPD: A Feasibility Study. (randomized trial)
- Malhotra et al., 2023. The Impact of a Wearable Activity Tracker and Structured Feedback Program on Physical Activity in Hemodialysis Patients: The Step4Life Pilot Randomized Controlled Trial. (randomized trial)
- Bertolet et al., 2026. Design, rationale, and baseline patient characteristics for the Sickle Cell Disease and CardiovAscular Risk-Red cell Exchange (SCD-CARRE) trial. (trial plan, no results yet)
- Ekelund et al., 2024. Dose-response associations, physical activity intensity and mortality risk: A narrative review. (opinion or narrative review)
- Xiang et al., 2022. Physical activity and chronic obstructive pulmonary disease: a scoping review. (systematic review)
- Del Pozo Cruz et al., 2022. Association of Daily Step Count and Intensity With Incident Dementia in 78 430 Adults Living in the UK. (population study: followed a group)
- Hernández-Vicente et al., 2019. Physical Activity and Sedentary Behavior at the End of the Human Lifespan. (population study: one-time survey)
- Janssens et al., 2023. A metabolomic signature of decelerated physiological aging in human plasma. (other)
- de Havenon et al., 2024. Impact of sleep quality and physical activity on blood pressure variability. (population study: followed a group)
- Wu et al., 2021. Acute Exacerbation of a Chronic Obstructive Pulmonary Disease Prediction System Using Wearable Device Data, Machine Learning, and Deep Learning: Development and Cohort Study. (population study: followed a group)
- Mach et al., 2020. Fitness-Tracker Assisted Frailty-Assessment Before Transcatheter Aortic Valve Implantation: Proof-of-Concept Study. (population study: followed a group)
- Biener et al., 2020. Endoscopic Lung Volume Reduction in COPD: The Impact of Coil Implantation on Patients' Physical Activity. (population study: followed a group)
- Zetterberg et al., 2025. Physical activity levels and associated biopsychosocial characteristics among attendees to exercise-based cardiac rehabilitation. (population study: one-time survey)
- Ganer Herman et al., 2020. Mobility following cesarean delivery: an observational study utilizing pedometers. (population study: followed a group)
- Kobayashi et al., 2024. Four-year mortality and physical activity in Japanese patients with chronic obstructive pulmonary disease. (population study: followed a group)
- Tison et al., 2018. Passive Detection of Atrial Fibrillation Using a Commercially Available Smartwatch. (population study: followed a group)
- Nishi et al., 2024. Association between daily step counts and healthy life years: a national cross-sectional study in Japan. (population study: one-time survey)
- Kimura et al., 2023. Lifestyle factors that affect cognitive function-a longitudinal objective analysis. (population study: followed a group)
Words on this page
- Hazard ratio (HR)
- Compares how often something happened in two groups over time. 1 means no difference. 0.80 means 20% lower risk; 1.20 means 20% higher.
- Pooled review (meta-analysis)
- A study that combines the results of many earlier studies to get one overall answer.
- Umbrella review
- A review of many pooled reviews.
- Cohort study
- A study that follows a large group of people over years. It shows links, not causes.
How the short answer is set
Fixed rules turn the studies into the short answer, so the same studies always give the same answer. The rules start from GRADE, a standard system for rating evidence, in plain language.
| Confidence | What it means |
|---|---|
| High | We are confident the answer is right. |
| Moderate | The answer is probably right, but it could change. |
| Low (this page) | The answer may well change. |
| Very low | Any answer is very uncertain. |
| Not tested in people | Only cell or animal studies exist. |
Why low here
- Only population studies; no trial assigned step counts and counted deaths.
- Clear dose-response: more steps went with lower death risk almost everywhere.
- Reviews disagree on where benefit levels off; two saw lower risk past 10,000.
- Illness lowers steps, so sick people may make the link look stronger.
Hard limit used. With no trial that assigned step counts and tracked deaths, the answer cannot say that more steps cause a longer life.
How this page was made
Label
- Search
- PubMed, Nov 14, 2026. Searches written by Claude Opus 5.5; papers ranked by PubMed
- First read of all 54 papers
- Claude Sonnet
- Independent second read
- Claude Haiku
- Disagreements settled by
- Claude Opus 5.5
- Page text written by
- Claude Opus 5.5
- Charts
- Drawn by code from the study records
- Source check by a person
- Not yet. Required before search engines may list this page.
- Expert review
- No
- Papers read in full
- 0 of 54; all from PubMed abstracts
- Method
- v0.2, created Nov 14, 2026
Search. We ran four PubMed searches for daily step count and death from any cause: pooled and systematic reviews since 2012 (10 of 42), trials in people (22 of 79), population studies (22 of 130). The first number is how many papers we read; the second is how many PubMed found. We took the ones PubMed ranks as most relevant. See the full PubMed search. Of the 54 papers read, 17 were on topic.
Limits. Digestery reads at most about 60 papers per question, so large fields are sampled, not covered in full. Abstracts can leave out key details, such as side effects and funding.
Review queue
These items wait for a person. Search engines are asked not to list the page until the first one is done.
- OpenThe short answer is new. It waits for a source check by a person.
- OpenKobayashi 2024 links activity level to death in COPD, but the abstract never says step count. Kept off-topic; check full text.
- OpenCoelho-Júnior 2026 and Mach 2020 use steps only inside combined scores that predict death. Kept off-topic; confirm.
- OpenDurheim 2015, Manz 2024 and Alver 2024 combine death with hospital stays or heart disease. Counted relevant as mixed outcomes; confirm.
- OpenPooled reviews Paluch 2022, Banach 2023, Jayedi 2022, Rodríguez-Gutiérrez 2024, Stens 2023 and Ding 2025 may share cohorts; check overlap before treating them as independent.
- OpenInoue 2023 and Wang 2026 both use NHANES 2005-2006; Del Pozo Cruz 2022 and Del Pozo Cruz 2025 both use UK Biobank. Not independent samples.
- OpenNo COI statement in PubMed for Jayedi 2022, Durheim 2015 and Wang 2026; Del Pozo Cruz 2025 disclosures are only online.
- OpenHamaya 2024 marked company stake for a DeSC Healthcare consulting fee; the record does not say what that firm sells. Confirm.
- OpenRahmati 2025 abstract says 'Frothy-eight' meta-analyses; read as 48. Check the typo.
Page history
| Date | Change | Reason |
|---|---|---|
| Nov 14, 2026 | Page created from 54 papers. | First version of the page. |
Flag an error
A flag must point to a source: the passage in the paper, or a link to a study this page missed. A flag starts a new check. Votes never change a page.